Search Results

Rutgers University and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured and underinsured patients of the university’s Health Outreach Practice Experience Clinic in Plainfield, NJ.

Clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions and present their latest discoveries from their innovative cancer research program at the 2024 American Society of Clinical Oncology Annual Meeting, to be held in Chicago from May 30-June 4.

Heart Test Laboratories, Inc.d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) today announced that it has entered into a multi-year collaboration agreement with Rutgers University (Rutgers), one of America’s leading public research universities.

Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology’s industry-leading personalized MRD technology to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

NexImmune, Inc. today announced a collaboration with Rutgers, The State University of New Jersey.

Heart Test Laboratories, Inc d.b.a HeartSciences announced that management has been invited to participate and showcase the company’s technology at the Inauguration Ceremony of the Center for Innovation at the Rutgers Robert Wood Johnson University Hospital on September 14, 2022, in New Brunswick, New Jersey.